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Sir,
Re: elevated level of circulatingmatrix
metalloproteinase-9 inpatientswith lung
cancer (Respir Med 2001; 95: 1^4)We read with interest the paper by Hrabec et al. (1) on
the concentrations of matrix metalloproteinase 2 and 9
(MMP-2, MMP-9) in blood of patients with lung cancer.
They reported the observation that the levels of MMP-9
measured in serum or plasma of lung cancer patients
were signi¢cantly increased compared to normal con-
trols while MMP-2 concentrations were unchanged.The
authors concluded that this phenomenon is not simply
due to an over-expression of this enzyme in cancer cells.
From our point of view the authors have not taken
into account that analytical problems in analysing the
MMP levels in serum may arise and therefore in£uence
the results (2).Our previous studies showed distinct dif-
ferences in MMP-9 levels between serum and EDTA or
heparin plasma (3). In serum samples higherMMP-9 were
detected compared to plasma samples.
These studies demonstrated the importance of a stan-
dard preanalytic procedure for the collection of speci-
men and themeasurement of MMPs and TIMPs in blood.
We inferred from these data that heparin plasma shouldFIG. 1. MMP-9 and MMP-2 concentrations in dependence on samp
and plasma derived from blood samples of eight healthy persons c
negativetubeswithno additive; serum-positive: tubeswithkaolin-c
EDTA:EDTAcoatedtubes, citrate: citrate coatedtubes).Themeasur
The results are expressed as boxes andwhiskers (boxeswiththe h
centiles; whiskers show therange ofthe data).Data betweengroup
ences (at least Po0  05) were between MMP-9 values in both kin
samples, respectively. In MMP-2 measurements, no di¡erences (P4
and EDTAplasma samples but all these samples showedhigher analbe used as sample to avoid pre-analytical mistakes for
MMP-9measurements.This is generally in linewith other
reports that have recommended plasma samples for
MMP-9 determinations in blood (4). We have extended
our study on the e¡ect of sample preparation on the
measurement of MMP-9 and MMP-2 in blood to investi-
gate the in£uence of di¡erent blood sampling tubes on
MMP levels.To investigate the e¡ect of blood collection
on MMP-9, venous blood samples from eight healthy
volunteers were simultaneously collected in various
devices for preparation of serum samples, namely: (1)
S-Monovette Neutral tubes 01 1728 (plastic tubes with
no additive for preparation of native serum, indicated in
the following as serum-negative; (2) S-Monovette Serum
tubes 011601 (plastic tubes with kaolin-coated plastic
granulate coagulation accelerator for preparation of ser-
um, indicated in the following as serum-positive; (3)
S-Monovette plastic tubes coated either with lithium
heparin, potassium EDTA or sodium citrate for prepara-
tion of plasma samples (all the devices were from Sar-
stedt GmbH, Nˇrnberg,Germany). The tubes stored at
room temperature were centrifuged within 30^60min
after venipuncture at1600g for15min.The supernatants
were carefully removed, centrifuged again at 10000g,
and stored at ÿ801C until analysis was performed.We
used ELISAs for MMP-2 and MMP-9 supplied by Amer-
sham Pharmacia Biotech, Little Chalfont, U.K. Onco-
gene, Boston MA,U.S.A and Medac Diagnostika,Wedel
Germany.le processing.MMP-9 (a) and MMP-2 (b) weremeasured in serum
ollected in Monovette systems from Sarstedt (Germany) (serum-
oatedgranulate asclot activator; heparin: heparin-coatedtubes,K-
ementswereperformedwiththeMedacMMP-9 andMMP-2 assay.
orizontal line atthemedian extend fromthe 25thto the 75th per-
swere comparedusing the t-test forpaireddata.Signi¢cant di¡er-
ds of serum samples and plasma samples and among all plasma
0  05) were found between both serum preparations, heparin
yte concentrations than citrate plasma.
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serum depending on the clotting surface of the
tubes used for sample collection compared to heparin
and EDTA plasma (Fig. 1). Increased values in serum
are supposedly caused by the release of MMP-9 during
platelet activation and clottingprocess.These important
preanalytical conditions should be considered
in the interpretation of increased MMP levels. Hrabec et
al. did not clearly distinct between serum or plasma
samples that may lead to misinterpretations. This
point would ¢t in their conclusion which assumed that
mechanisms additional to enzyme over-expression in
lung cancer may be responsible for the enhanced MMP
levels.
The pre-analytical sampling is therefore an important
feature for the MMP measurement in the blood regard-
less of the method which is ¢nally used for the enzyme
quanti¢cation.Webelieve that it is necessary to consider
this fact in future studies on the clinical validity of MMP
measurements in blood.
M. JOHN,U.OLTMANNS,C.WITT and K. JUNG
Department of Pneumology and
Clinic of Urology,University Hospital Charite¤ ,
Humboldt University,
Berlin,Germany
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Sir,
Re: Elevated level of circulatingmatrix
metalloproteinase-9 inpatientswith lung
cancer (Respir Med 2001; 95: 1^4): a reply
We are aware of the letter by Dr M. John and colleagues
to the Editor of RespiratoryMedicine aswell as the results
of their study on the role of specimen collection in the
measurement of matrix metalloproteinases (MMPs) and
matrix metalloproteinase inhibitors (TIMPs) publishedearlier (1).We of course agree with Dr John that appro-
priate selection of specimens is very important for cor-
rect evaluation of MMPs activities in blood.
The studies conducted in other laboratories in the
1990s showed that serum or plasma type IV collagenase
levels are signi¢cantly elevated in many neoplastic dis-
eases and it has been suggested that the rise in circulat-
ing MMP-2 and/or MMP-9 levels in cancer patients
re£ects enhanced secretion of these enzymes in tumour
area (2,3). Using a zymographic test we analysed the
type IV collagenases levels in serum samples of lung can-
cer patients and healthy volunteers, hoping that MMP-2
activity would be elevated in lung cancer sera, since our
previous study showed that this enzyme is predomi-
nantly over-expressed in lung cancer tissue as compared
to normal lung parenchyma (4). However, the serum le-
vels of MMP-2 in lung cancer patients were similar to
those of healthy donors, whereas MMP-9 levels were
3?59-fold higher in lung cancer.We presented the results
of this study in our article (5). Since the di¡erences be-
tween normal and cancer sera concerned MMP-9, but
not MMP-2, we took into consideration the results of
the study reported by Dr John and colleagues (6) and
tested these activities also in plasma samples. In the zy-
mographic test we compared the serum and plasma le-
vels of type IV collagenases from the same individuals
(lung cancer patients andhealthy volunteers).Forplasma
preparation venous blood samples were collected into
lithium heparin-coated plastic tubes (Vacuette-Greiner
Labortechnik, Ko¤ dzŁ , Poland). These results were also
presented in our article (5).We showed that MMP-2 le-
vels tested in serum and plasma specimens were similar
in the range of analytical precision and did not di¡er be-
tween both groups tested (normal and cancer), whereas
MMP-9 levels tested in serumwere about two foldhigher
than in plasma samples. However, the MMP-9 activities
tested in plasma of lung cancer patients were 3?42-fold
higher than in plasma from normal individuals.Thus, the
di¡erences in MMP-9 levels between cancer and normal
samples tested in plasmawere similar to those obtained
for serum.Wewish to emphasize that in each case com-
parisons were made between consistent specimens (i.e.
MMP-9 activities in cancer plasma samples were com-
pared with normal plasma samples and MMP-9 activities
in cancer serum samples were compared with normal
serum). In the ¢rst version of our manuscript submitted
to Respiratory Medicine we inserted a ¢gure illustrating
the di¡erences between serum and plasma levels of
these enzymes evaluated by zymography. However, by
request from the Editor, we shortened our article and
this ¢gure was not published. Now, for a better illustra-
tion of the results of the study we present this ¢gure
(Fig.1).
We do not believe that increased MMP-9 values ob-
served in serum are a result of releasing of this enzyme
from platelets during their activation and clotting pro-
